Prostate cancer cells grow with malfunction of cholesterol control in cells

February 21, 2017 by Sarah Avery

Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem.

Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that hijack to hoard and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients.

The findings are published online this month in the journal Cancer Research.

"Prostate cancer cells, as well as some other solid tumors, have been shown to contain higher cholesterol levels than normal cells," said senior author Donald McDonnell, Ph.D., chairman of the Department of Pharmacology and Cancer Biology at Duke. "All cells need cholesterol to grow, and too much of it can stimulate uncontrolled growth.

"Prostate cancer cells somehow bypass the cellular control switch that regulates the levels of cholesterol allowing them to accumulate this fat," McDonnell said. "This process has not been well understood. In this study, we show how accomplish this."

McDonnell and colleagues began by identifying genes involved in cholesterol regulation in . They homed in on a specific gene, CYP27A1, which is a key component of the machinery that governs the level of cholesterol within cells.

In patients with prostate cancer, the expression of the CYP27A1 gene in tumors is significantly lower, and this is especially true for men with aggressive cancers compared to the tumors in men with more benign disease. Downregulation of this gene basically shuts off the sensor that cells use to gauge when they have taken up enough cholesterol. This in turn allows accumulation of this fat in tumor cells. Access to more cholesterol gives cells a selective growth advantage.

"It remains to be determined how this regulatory activity can be restored and/orwhether it's possible to mitigate the effects of the increased cholesterol uptake that result from the loss of CYP27A1 expression," McDonnell said.

He said statin use alone might help, but perhaps not enough, since tumors could simply rev up the regulation of the cholesterol manufacturing process in tumors to compensate.

McDonnell said is lab is continuing the research, including finding ways to induce cells to eject cholesterol, reverse the inhibition of CYP27A1 activity, or introduce compounds that interfere with cholesterol-production in the .

Explore further: Potential cholesterol-lowering drug molecule has prostate cancer fighting capabilities

More information: Mahmoud A Alfaqih et al. CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer, Cancer Research (2017). DOI: 10.1158/0008-5472.CAN-16-2738

Related Stories

Recommended for you

How cancer cells flood the lung

May 19, 2017

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the ...

Cancer immunotherapy may work in unexpected way

May 18, 2017

Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body's T cells, a type of immune cell. Now, researchers at the Stanford University School of Medicine have shown that the therapy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.